30 C
Vientiane
Monday, June 9, 2025
spot_img
Home Blog Page 772

Review and Outlook of Sanyou Bio Intelligent Super-trillion Molecule Discovery Platform

SHANGHAI, Feb. 23, 2025 /PRNewswire/ — On February 15, 2025, Sanyou Bio conducted a full review of its Intelligent Super-trillion Molecule Discovery Platform. As the core technology of the platform, the intelligent super-trillion molecule library boasts a library capacity of up to 10 trillion, enabling the screening and identification of hundreds to thousands of lead molecules for a single target. By integrating high-through eukaryotic expression verification and multidimensional druggability analysis, the platform significantly improves the efficiency of innovative biological drug R&D and plays a key role in novel macromolecule drug discovery.

Sanyou Bio’s Intelligent Super-trillion Molecule Discovery Platform consists of ten sub-platforms, encompassing a variety of molecular types. These include super-trillion fully human antibody discovery platform, super-trillion common light chain antibody discovery platform, super-trillion 2C type single-domain antibody discovery platform, super-trillion 4C type single-domain antibody discovery platform, super-trillion cyclic peptide discovery platform, super-trillion novel targeting protein discovery platform, magnetic-array mouse immune antibody discovery platform, magnetic-array alpaca immune antibody discovery platform, magnetic-array rabbit immune antibody discovery platform, and magnetic-array canine immune antibody discovery platform.

Details of the ten sub-platforms are summarized in Table 1. Each sub-platform has unique characteristics and can be widely applied in therapeutic, diagnostic, detection and scientific research fields. So far, the Intelligent Super-trillion Molecule Discovery Platform has completed over 650 molecule discovery projects, advancing more than 100 PCC projects, with several projects have entered the clinical stage. This further demonstrates the capability of Sanyou Bio’s platform to complete the development of mainstream drug molecules such as monoclonal antibody drugs, bispecific antibody drugs, multi-specific antibody drugs, ADC drugs, AOC drugs, RDC drugs, PDC drugs, and CAR-T immune cell therapy.

Table 1. Applications and Advantages of the Intelligent Super-trillion Molecule Discovery Platform

No

Library

Library
Capacity

CDR3
length

Characteristics

1

Super-trillion fully
human antibody
discovery platform

2.16 x 1012

5~28

Direct acquisition of fully human antibody sequences with
high antibody diversity; capable of obtaining hundreds of
lead molecules

2

Super-trillion
common light chain
antibody discovery
platform

1.12 x 1012

4~26

Common light chain with excellent druggability and high
heavy chain diversity; capable of obtaining hundreds of
lead molecules

3

Super-trillion 2C
type single-domain
antibody discovery
platform

2.13 x 1012

12~19

Humanization level up to 98%, enabling the discovery of
antibody drugs for high-difficulty targets

4

Super-trillion 4C
type single-domain
antibody discovery
platform

1.94 x 1012

14~21

Humanization level up to 98%, with excellent molecule
stability and resistance to degradation; antibody affinity
reaching pM level

5

Super-trillion cyclic
peptide discovery
platform

3.05 x 1012

4~17

High diversity; optimized fusion with tag proteins for
natural peptides, enabling eukaryotic expression,
purification, and mass production

6

Magnetic-array
mouse immune
antibody discovery
platform

7.10 x 1011

4~15

Fast screening speed, the process is nearly three months
shorter compared to hybridoma screening technology;
antibody affinity reaching pM level

7

Magnetic-array
alpaca immune
antibody discovery
platform

2.83 x 1011

3~27

Capable of obtaining a large number of antibody
molecules for high-difficulty targets, covering most of the
protein epitopes

8

Magnetic-array
rabbit immune
antibody discovery
platform

4.88 x 1010

6~20

Abundant types of immune raw materials and diverse
screening methods;easy to obtain high-specificity, high-
affinity antibodies

9

Magnetic-array
canine immune
antibody discovery
platform

4.21 x 109

5~20

Direct acquisition of canine-derived monoclonal
antibodies, no need for caninization; filling the gap in pet
monoclonal antibody market

10

Super-trillion novel
targeting protein
discovery platform

6.00 x 1010

4~8

Stable protein backbone structure with low
immunogenicity; variable regions avoid modification
sites, and molecules obtained have high druggability

Part 1 Review of the Intelligent Super-trillion Molecule Discovery Platform

1. Super-trillion fully human antibody discovery platform

Library background and history

Phage display technology is a crucial way to develop fully human antibodies, demonstrating advantages over hybridoma antibody technology in many aspects. Currently, human phage display antibody libraries on the market face challenges such as limited donor sources, low library capacity, low diversity, low affinity, and low druggability. To address these issues and obtain more candidate antibodies with better quality, Sanyou completed the conceptual design of the sub-trillion fully human antibody library in 2017, focusing on antibody backbone sequences with higher druggability and avoiding the presence of pseudogenes at the same time. By 2018, the sub-trillion fully human antibody library was constructed and validated. To further expand the library capacity, Sanyou completed the conceptual design of the super-trillion fully human antibody library and the super-trillion fully human semi-synthetic antibody library in 2019 and 2020 respectively. By 2021, both antibody libraries were constructed and validated.

Library composition and characteristics

Sanyou’s super-trillion fully human antibody discovery platform consists of two major libraries: super-trillion fully human antibody library and super-trillion fully human semi-synthetic antibody library, with a total library capacity of 2.16 trillion. The super-trillion fully human antibody library is a recombinant antibody library after gene cloning of human B cells. It is derived from nature with excellent druggability and the median number of lead molecules obtained is 300+. The super-trillion fully human semi-synthetic antibody library is derived from human B cells after gene rearrangement with engineering design. It offers high diversity with a median number of lead molecules obtained also at 300+.

Library cases and applications

So far, Sanyou has completed over 200 single-target screenings using fully human antibody library. The lead molecules obtained from super-trillion fully human antibody library can reach hundreds. As shown in Figure 1, through screening and validation across 11 different targets, a total of 5,069 fully human antibody clones with unique sequences were obtained, and the median number of clones was 345 per target. The affinity of molecules screened from Sanyou’s super-trillion fully human antibody library often ranges from sub-nM to nM levels. Figure 2 shows the affinity analysis of expressed supernatant samples. The results reveal that the majority of antibody clones exhibit affinities in the 10⁻⁸ to 10⁻¹⁰ range.

2. Super-trillion common light chain antibody discovery platform

Library background and history

Bispecific antibodies with a common light chain configuration can effectively solve the issue of light-heavy chain mismatch, and are highly consistent with natural IgG-type antibodies in structure. Compared with various non-human bispecific antibody configurations, bispecific antibodies with a common light chain configuration offers better druggability and safety profiles in human body. Sanyou completed the preliminary conceptual design of the common light chain antibody library, and conducted preliminary research on common light chain antibodies in 2017. Then completed the construction of the billion-level common light chain antibody library in 2018, and the validation of the billion-level common light chain antibody library in 2019. In 2020, the concept design of the super-trillion common light chain antibody library was completed, and 2 exceptional light chains were selected from over 1800 light chains through rigorous screening. The construction and validation of the super-trillion common light chain antibody library was completed in 2022.

Library composition and characteristics

Sanyou’s super-trillion common light chain antibody discovery platform is composed of 2 light chains and 6 sub-libraries with a total library capacity of 1.12 trillion. It is a recombinant antibody library by selecting 2 exceptional light chains paired with a diverse set of heavy chains. The library is derived from fully human natural antibodies, with carefully selected light chains for optimal performance and diverse heavy chains. The median number of lead molecules obtained is 300+. Common light chain antibodies targeting different epitopes of the same target or different targets can be screened in one step; the obtained common light chain antibodies are fully human antibodies and can be directly used for downstream bispecific antibody development.

Library cases and applications

So far, Sanyou has completed over 30 screenings using common light chain antibody library. For different targets, an average of hundreds of lead antibody molecules with unique sequences and good affinity can be obtained. As shown in Figure 3, through screening and validation across 7 different targets, a total of 4,942 common light chain antibody clones with unique sequences were obtained, and the average number of unique sequence clones was 706 per target. The binding activity of candidate antibodies obtained from the human library (hRAL) and the common light library (CLC) was detected by ELISA. Figure 4 reveals that the proportion of hRAL candidate antibodies with EC50 between 0.01 and 0.1 was 94.44%, while the proportion of CLC candidate antibodies with EC50 between 0.001 and 0.01 was 78.95%, indicating CLC antibodies have higher affinity.

3. Super-trillion single-domain antibody discovery platform

Library background and history

Humanization of single-domain antibodies can significantly reduce the immunogenicity of camel-derived antibodies and accelerate the production and commercialization of antibody-based drugs. To overcome the defects of traditional single-domain antibody preparation technology, such as long preparation cycles, heavy screening workloads, and small number of lead candidates, Sanyou’s super-trillion single-domain antibody discovery platform has undergone four generations of library upgrades: completion of the construction and validation of the 10-billion single-domain naïve library in 2018; completion of the construction and validation of the sub-trillion single-domain antibody library in 2019; completion of the humanized single-domain conceptual design using a humanized backbone for library construction, and at the same time design of sub-libraries with only 1 pair of cysteines and 2 pairs of cysteines; completion of the construction and validation of the super-trillion humanized single-domain antibody library in 2021.

Library composition and characteristics

Sanyou’s super-trillion single-domain antibody library is constructed using internationally advanced primer synthesis technology and a humanized backbone with excellent druggability, ensuring superior therapeutic potential. This platform has independent intellectual property rights and is supported by comprehensive physicochemical and biomedical analyses for efficient screening. The platform comprises two major sub single-domain synthetic libraries 2C-type and 4C-type. There are further divided into 16 sub-libraries with a total library capacity of 4.07 trillion. The humanization degree of the antibody backbone reaches 98% and the median number of lead molecules obtained is over 600.

Library cases and applications

So far, Sanyou has completed over 60 screenings using single-domain antibody library. As shown in Figure 5, through screening and validation across 14 different targets, a total of 9,423 humanized single-domain antibody clones with unique sequences were obtained, and the median number of clones was 606 per target. The affinity of nanobody candidate molecules screened from Sanyou’s super-trillion humanized single-domain antibody library has excellent affinity and often reaches pM levels. Figure 6 shows the affinity analysis of full-length constructed molecules. The results reveal that the majority of antibody clones exhibit very high affinities.

4. Super-trillion cyclic peptide discovery platform

Library background and history

According to statistics, the global peptide drug market reached $62.8 billion in 2020 and is expected to grow to $96 billion by 2025, highlighting the significant growth potential in this sector. Peptide-based drugs offer the advantages of high specificity, low immunogenicity, less toxic side effects, and the applicability to intracellular targets. The establishment of peptide libraries is crucial for peptide drug R&D, but constructing such libraries requires substantial time and financial investment for most drug R&D companies. To address this challenge, Sanyou completed the construction and validation of the sub-trillion cyclic peptide library in 2022 and further advanced to the super-trillion cyclic peptide library in 2023, significantly enhancing the efficiency and success rate of peptide drug discovery.

Library composition and characteristics

Sanyou’s super-trillion cyclic peptide library follows natural design principles, supplemented by AI-driven design, fused with tag proteins, combined with phage display technology for high-throughput screening, and matched with comprehensive physicochemical and biochemical analyses for further validation. The library has a total of 19 sub-libraries, with peptide lengths ranging from 4 to 17 amino acids and a total library capacity of 3.05 trillion. The cyclic peptide platform integrates optimized tag protein with natural cyclic peptide and is suitable for PDC, oral, and intracellular target drug development, with a median number of lead molecules obtained of 60+.

Library cases and applications

So far, Sanyou has completed over 20 screenings and validation using cyclic peptide library. As illustrated in Figure 7, the peptide molecule A083, obtained from the super-trillion cyclic peptide library, underwent affinity maturation and was evaluated for ELISA binding activity using huPD-L1 antigen protein. The EC50 of antigen-binding was approximately 0.04 nM, comparable to the affinity of the reference antibody. Additionally, A083 demonstrated a 10-fold improvement in blocking activity, compared with the reference antibody. Figure 8 reveals that the EC50 for blocking the interaction between huPD1 and huPD-L1-CHO-K cells was 5.7 nM,

5. Magnetic-array immune antibody discovery platform

Library background and history

Sanyou Bio established its proprietary phage display vector platform in 2015, and applied the “multi-pathway antigen and antibody library” technology to the development of innovative antibody drugs. In 2016, we integrated hybridoma technology and phage display technology to promote the commercialization of the mouse immune antibody library. In 2017, the mouse immune library underwent a significant upgrade by incorporating array-based primers to further improve library diversity. The alpaca immune antibody library was launched in 2018, and afterwards, the rabbit immune antibody library and the canine immune antibody library were established in 2023 and 2024 respectively.

Library composition and characteristics

Sanyou’s magnetic-array immune antibody library includes: mouse immune antibody library, alpaca immune antibody library, rabbit immune antibody library and canine immune antibody library, with a total library capacity of 1.05 trillion. The specific parameters of each immune library are shown in Table 2. Antibodies can be produced for different target types (including small molecules). The number of nanoantibody lead molecules obtained through the screening of the Sanyou magnetic array immune antibody library is large, usually reaching dozens of molecules, with high molecular affinity. The library has broad target coverage, capable of screening antibodies against diverse targets, including small molecules and high yield of lead molecules, typically dozens per target with excellent affinity.

Table 2. Technical specification of the magnetic-array immune antibody library

No

Library

Library
capacity

Targets
completed

Characteristics

1

Magnetic-array
mouse immune
antibody discovery
platform

7.10  x 1011

263

1. Direct acquisition of antibody sequence to
accelerate the progress of project development

2. Multi-point and diverse immunization, easy to
obtain cross-species reactive antibody molecules

3. Capable of delivery of dozens to hundreds of
lead molecules

2

Magnetic-array
alpaca immune
antibody discovery
platform

2.83  x 1011

180

1. Defined antibody sequence to reduce
redundant screening workloads

2. Capable of delivery of dozens to hundreds of
lead molecules

3. Coverage on high-difficulty and hidden-
epitope targets

3

Magnetic-array
rabbit immune
antibody discovery
platform

4.88  x 1010

36

1. Single subtype, easy to humanize

2. Diverse immunization strategy, easy to obtain
antibodies with high affinity

3. Suitable for diagnostic antibody development

4

Magnetic-array
canine immune
antibody discovery
platform

4.21  x 109

10

1. Fill the gap in the pet monoclonal antibody
market

2. Simplify the technical difficulty of
caninization

3. Canine monoclonal antibodies have a longer
half-life

Library cases and applications

So far, Sanyou has completed over 480 screenings using immune antibody library. As illustrated in Figure 9, through screening and validation across 12 different targets, a total of 637 antibody clones with unique sequences were obtained, and the median number of clones was 55 per target. The affinity of antibody molecules screened from immune antibody library construction and screening service usually reaches pM levels. Figure 10 shows the affinity of the molecules screened from immune antibody library is comparable to or significantly better than that of the reference antibody.

Part 2 Development of the Intelligent Super-trillion Molecule Discovery Platform

1. Construction plan of the 100-trillion molecule library platform

Sanyou Bio remains committed to its mission of “making innovative biologics easier worldwide”. Building upon the foundation of the Intelligent Super-trillion Molecule Discovery Platform, we are now advancing the development of the 100-trillion Molecule Library Platform, driven by R&D and innovation to promote the development of the specialized services. Based on the current molecule library, the 100-trillion molecule library in future will achieve: 1) the library types will be expanded on top of the existing 10 sub-libraries to further diversify by incorporating nucleic acid libraries, small peptide libraries, and small molecule libraries. By 2027, the total library capacity is projected to reach 100 trillion; 2) the design of the library will be further optimized through AI assistance, the molecule diversity and performance will be further improved based on massive data analysis, and the customized construction of novel molecule library will be carried out; 3) through AI-driven drug screening, the screening efficiency will be accelerated, the R&D cycle will be shortened, and the success rate of new drug discovery will be enhanced.

2. Construction plan of the intelligent drug screening platform

The intelligent drug development platform aims to revolutionize antibody drug discovery through virtual screening and design optimization technology powered by generative AI models. This innovative approach will significantly improve drug development efficiency, and help solve the current issues of long antibody drug development cycle, high cost and low success rate. The intelligent drug development platform will greatly shorten the drug development cycle and enhance the success rate.

The intelligent drug screening platform plans to further develop AI-driven drug screening and other applications based on multiple applications such as the oneClick+ bispecific antibody design platform that have been launched. Main applications include: 1) De novo molecule generation, by utilizing AI algorithms to design and generate of molecular structures with specific properties and functionalities. Break through the traditional discovery model, enabling the design and development of first-in-class drugs, and expand the scope and possibilities of drug development; 2) Coding sequence optimization, through AI-powered sequence optimization to enhance the druggability and stability of the molecules; 3) Innovative molecule library design, based on AI-driven big data analysis to design and construct next-generation molecule libraries with improved efficiency and success rate of drug screening and discover more molecules with potential application value. This will further solve the drug development issues of high-difficulty targets such as GPCRs, ion channels, and intracellular proteins, and develop new drug delivery methods such as oral administration. The rapid development of these technologies enables us to discover drug targets with higher efficiency and shorter time, create biologics that meet clinical needs, and respond to diverse scientific and medical challenges.

3. Prospects of the development of the intelligent super-trillion molecule library

Traditional drug discovery often faces challenges such as long development cycles and high costs. In contrast, the intelligent super-trillion molecule library platform, powered by AI-driven technologies, accelerates the discovery and development process, reduces costs, and enhances efficiency.

Looking into the future, Sanyou Bio’s intelligent super-trillion platform will develop in a more intelligent direction. In terms of development direction, it explores towards 5 major directions, including indications, molecular formats, application scenarios, mini-programs, and important targets. In terms of molecular types, it covers 6 types of molecules, including fully human monoclonal antibodies, common light chain antibodies, humanized single-domain antibodies, cyclic peptide molecules, ADC molecules, and mRNA molecules, proving diversified molecular tools for the treatment of different diseases. In terms of application scenarios, it is adapted to 8 key scenarios, including ELISA, WB, IHC, IF, IP-ID, FC, SPA, and SPB. In terms of technology integration, 7 AI-driven programs are integrated, including de novo generation, epitope prediction, immunogenicity prediction, druggability prediction, specificity prediction, affinity predication, and one-click molecule design, to improve the intelligence level of R&D. In terms of disease research, it focuses on 9 major human diseases, including tumors, autoimmune, infection, metabolism, ophthalmology, neurology, cardiovascular, anti-aging, and various rare diseases. In terms of target exploration, it concentrates on in-depth research over 100K important targets by integrating 10 major technology platforms to lay a solid foundation for the development of more innovative drugs.

After 10 years of relentless effort and technological innovation, Sanyou Bio’s intelligent super-trillion molecule library platform has established a world-leading antibody drug discovery system. With the design of super-trillion molecule library and ten categories of molecule libraries, the platform has successfully solved the key difficulties in the discovery of innovative macromolecule drugs and has broad application prospects, especially in the fields of tumor treatment, infectious disease prevention and treatment, autoimmune diseases and rare diseases. The ability of high-efficiency screening, precise optimization and rapid evolution provides strong support for the development of global antibody drugs. In the next five years, the current library will continue to be upgraded to the 100-trillion molecule library. Combined with AI power and high-throughput screening technology, it will be able to predict the properties of drugs more accurately, thus significantly improving the efficiency and success rate of drug development. This will greatly expand our space for exploring potential drug molecules and accelerate the process of new drug discovery. Sanyou Bio will continue to promote in-depth collaboration with professional teams globally to jointly accelerate the process of drug R&D in high-difficulty disease areas and bring more breakthrough treatment options to patients worldwide.

About Sanyou Bio

Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs. Sanyou has built the 4C business patterns that integrate “differentiated CRO, integrated CDO, innovative CPO and characteristic CRS”, to accomplish the mission “to make the R&D easy for innovative biologics”.

Sanyou has established an integrated innovative biologic drug R&D laboratory with advanced facilities, and has a professional team with the majority holding a Ph.D. or master degree. Sanyou has built three industry-leading innovative technology platforms featured by “super-trillion, integration, and intelligence” , which are comprised of more than 50 sub-platforms with the core innovative super-trillion phage display platform, and supported by platforms of material preparation, biologics discovery, molecule optimization, in vitro and in vivo efficacy, production cell line construction, upstream and downstream process development, preclinical R&D, industrialization development, etc.

Sanyou’s business network has expanded to all parts of the world, including Asia, US and Europe, and established branches in Boston, Philadelphia, San Diego and London. Sanyou has established friendly business relationships with more than 1000 pharmaceutical companies, drug R&D institutions and diagnostics companies worldwide. Sanyou received National-level certification as a high-tech enterprise and a Specialized and Sophisticated enterprise, and passed the ISO9001 quality assurance certification and GB/T intellectual property management system certification.

Over 3.2 million likes! Witsbb’s Australia Traceability Livestream Witnesses Quality Commitment, Allergen-Free Nutrition Gains Global Attention

SYDNEY, Feb. 23, 2025 /PRNewswire/ — After travelling over ten hours by plane, Chinese well-known blogger @Guo Xiaopang Couple reached Sydney, Australia, and started Witsbb’s traceability livestream, revealing the secrets behind its “allergen-free” nutrition. They demonstrated the brand’s commitment to quality and transparency by livestreaming Witsbb’s research capabilities and production chain. Winning over 3.2 million likes, the livestream triggered a phenomenal topic discussion and successfully set off a trend of scientific calcium supplementation in spring.

Over 3.2 million likes! Witsbb’s Australia Traceability Livestream Witnesses Quality Commitment, Allergen-Free Nutrition Gains Global Attention
Over 3.2 million likes! Witsbb’s Australia Traceability Livestream Witnesses Quality Commitment, Allergen-Free Nutrition Gains Global Attention

Against the iconic Sydney Opera House, @Guo Xiaopang Couple presented Witsbb’s top products, including “allergen-free” DHA, Lysine Calcium Magnesium Zinc PLUS, and Liquid Calcium Soft Capsules. Consumers were highly engaged, leaving comments like “My child is also taking it” and “Trust Witsbb for allergen-free nutrition.” Many mothers said the livestream increased their confidence in Witsbb’s products.

During the traceability journey, the couple visited Witsbb’s factory and offline pharmacies in Australia, providing a comprehensive view of the production process, quality control, and sales situation. Dr. John, a nutrition expert, was also invited to answer consumers’ questions of their principal concern on-site. He highlighted that Witsbb has passed the dual certifications of Australia’s TGA and the US FDA, emphasizing the brand’s commitment to product quality. In Australia, Witsbb’s Vitamin AD and liquid calcium products have long been top sellers.

Spring is the golden season for children’s bone growth, but calcium supplementation for infants and young children with sensitive constitutions requires more professional solutions. Witsbb’s scientific formula and pure ingredients make it a top choice for many mothers.

Dr. John said, “This 10,000-kilometer traceability journey is an important milestone in our commitment to the ‘allergen-free formula’ philosophy. We will continue to invest in research on allergen-free nutrition, constantly upgrading and innovating our formulas so that they can be enjoyed by more sensitive babies with confidence.”

As the livestream concluded with the night sky over Sydney Harbour, Witsbb reaffirmed its dedication to safe feeding through solid scientific research. Driven by the dual trends of consumption upgrade and scientific parenting, professional nutrition brands like Witsbb are ushering in a new era of precise infant and child health management.

Aeroband is selected as the exclusive music instrument brand for the 56th NAACP Image Awards® Official Celebrity Gift Lounge, celebrating innovation, music, and culture

Unleash the Rhythm of Greatness: Empowering Musicians Everywhere

LOS ANGELES, Feb. 23, 2025 /PRNewswire/ — Aeroband, the pioneer in smart music technology, is proud to announce that it is selected as the exclusive music instrument brand for the 56th NAACP Image Awards® Official Celebrity Gift Lounge, honoring Black excellence in entertainment, music, and culture. Through this partnership, Aeroband celebrates the creative power of music and its ability to transcend boundaries, just as the NAACP celebrates outstanding achievements in the arts.

Aeroband at the 56th NAACP Image Awards
Aeroband at the 56th NAACP Image Awards

Innovation Meets Music

Aeroband, a brand committed to breaking barriers in music innovation, celebrates the artists, creators, and changemakers who shape the world through their talent and passion. This partnership with the NAACP Image Awards reflects Aeroband’s core belief that music should be boundless—just like the impact of those honored at the event.

“Our mission is to give musicians, whether they are seasoned artists or newcomers, the freedom to create and perform without limitations,” said Frank Niu, Founder and CEO of Aeroband. “As the world’s leading smart musical instruments, Aeroband provides products like the Aeroband Guitar and PocketDrum, which allow music lovers to express themselves anywhere, anytime—whether they’re on stage, in a studio, or even in their living rooms. These products are designed to make music creation as intuitive and liberating as the diverse voices celebrated at the NAACP Image Awards.”

Campaign Highlights:

  • Exclusive Gifting: Celebrities and honorees will receive Aeroband Guitar and PocketDrum, unlocking new ways to experience music through cutting-edge technology.
  • Interactive Music Experience: VIP guests will have the opportunity to try Aeroband’s revolutionary instruments in a one-of-a-kind sound booth at the event.
  • Social Media Challenge: #UnleashTheRhythm – Fans and celebrities will showcase their Aeroband music skills, proving that music has no boundaries.

For more information, please visit https://www.aeroband.net/pages/the-naacp-image-awards

Aeroband Guitar: Aeroband Guitar is a smart, portable instrument perfect for music lovers. It features a built-in speaker, an external microphone, and connectivity to external speakers via a 1/4-inch output. The guitar offers multiple sound modes, including piano sound. As a new-generation guitar, the Aeroband Guitar makes practicing and learning easier than ever—allowing beginners to quickly learn. For creators, the Aeroband Guitar also offers MIDI functionality, opening up endless possibilities for music production and composition. Whether you’re a novice or a pro, this guitar empowers everyone to explore their musical creativity with ease.

  • Interactive lessons & real-time feedback
  • Multi-tone
  • Detachable neck for easy on-the-go use
  • MIDI controller

PocketDrum: PocketDrum is a portable, innovative air drumming instrument that transforms any surface into a responsive drum kit, allowing users to play anywhere, anytime. Perfect for drummers of all levels, PocketDrum offers an immersive, responsive experience that lets you explore rhythm and creativity anywhere, whether at home, in the studio, or on the go. Its quiet design ensures that you can practice without disturbing others, making it ideal for late-night sessions or shared living spaces. Additionally, PocketDrum features MIDI functionality, allowing you to connect to digital audio workstations and music production software, expanding your drumming capabilities to new levels of creativity.

  • Play anytime, anywhere
  • No disturb
  • Midi controller

Both the Aeroband Guitar and PocketDrum are available for purchase directly from our Aeroband website and on Amazon, making it easy for music lovers everywhere to access these innovative instruments. Whether you’re a beginner or a seasoned musician, these products are designed to bring out the best in your musical creativity.

About Aeroband

Aeroband as the world’s best smart musical instruments, dedicated to breaking barriers in music innovation. Known for its cutting-edge Aeroband Guitar and PocketDrum, the company enables users—from beginners to professionals—to explore their musical creativity anywhere, anytime.

About the NAACP Image Awards

The NAACP Image Awards is a prestigious event that honors outstanding achievements in the fields of entertainment, music, literature, and social justice. Celebrating Black excellence and cultural achievements, the awards are presented by the National Association for the Advancement of Colored People (NAACP). Since its inception, the NAACP Image Awards has been a platform to recognize and uplift the voices of Black artists, leaders, and activists who make significant contributions to the arts and society. The 56th NAACP Image Awards® Show will take place from the Pasadena Civic Auditorium, and will be broadcast live on Saturday, Feb. 22, 2025, at 8 p.m. ET/ 5 p.m. PT on BET.

Contact:
Lola Xu
Public Relations
Aeroband
Email: lola@aeroband.net
Website: https://www.aeroband.net

NetEase Cloud Music and Starship Entertainment Forge Copyright Partnership to Deliver Premium K-pop Content to Chinese Audiences

HANGZHOU, China, Feb. 23, 2025 /PRNewswire/ — Korean entertainment group Starship Entertainment has entered into a copyright partnership with China’s premier online music platform, NetEase Cloud Music. This agreement brings Starship’s complete catalog, including the latest hits from renowned Korean girl group IVE and their third mini album, “IVE EMPATHY,” to Chinese audiences. The partnership not only boosts Starship Entertainment’s profile in China but also diversifies the music offerings available to Chinese listeners with a wider array of musical styles.

The collaboration capitalizes on the unique strengths of both entities in content creation and distribution. NetEase Cloud Music, hailed as one of China’s top online music platform, enjoys widespread popularity among the nation’s youth. Its vibrant music community enhances the efficiency of music distribution and expands Starship Entertainment’s reach among young Chinese music fans. Official figures show that NetEase Cloud Music has 206 million monthly active users, with more than 31.4% engaging with recommended tracks, marking a shift from traditional listening habits to a more engaged and unified community.

K-pop continues to thrive on the NetEase Cloud Music platform, with numerous artists from Starship Entertainment already gaining substantial recognition and positive commentary on the platform. Notably, the girl group IVE boasts over 349,000 fans on NetEase Cloud Music, with several of their songs amassing more than 100,000 favorites shortly after release. This highlights K-pop’s growing impact within the NetEase Cloud Music community. 

The copyright partnership with Starship Entertainment is a significant milestone in NetEase Cloud Music’s ongoing commitment to strengthening its K-pop offerings. In recent years, the platform has established partnerships with major South Korean entertainment firms including SM Entertainment, JYP Entertainment, YG Entertainment, Kakao Entertainment, and CJ ENM. These alliances have enabled NetEase Cloud Music to continuously introduce high-quality K-pop music to the Chinese market. As a result, the platform has developed an extensive library of licensed K-pop music, establishing itself as a crucial gateway for Chinese music fans to explore and appreciate the genre.

Bybit Expresses Deep Gratitude as Crypto Industry Unites Against Security Threats

DUBAI, UAE, Feb. 23, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, extends its heartfelt thanks to the global crypto community for the overwhelming support received in the wake of a recent security incident. This unprecedented show of solidarity has not only reinforced Bybit’s resilience but has also laid the foundation for stronger industry-wide measures to counter and prevent future hacking incidents. From institutional liquidity providers to leading blockchain security firms, the swift and coordinated response has exemplified the strength of the Web3 community.

A United Front Against Threats

As soon as the incident was detected, Bybit’s security team took immediate action—locking down systems, securing funds, and collaborating with top cybersecurity experts. The exchange received overwhelming support from key players across the industry, all working together to track, contain, and mitigate the impact of the exploit.

Ben Zhou, Co-Founder and CEO of Bybit, expressed his gratitude:

“It’s been a challenging period for Bybit, but one thing is clear—our partners have our backs. The support from Antalpha Global, Bitget, Pionex, MEXC, SoSoValue, Galaxy Digital, FalconX, Lido Finance, Solana Foundation, Ton Foundation, Ghaf Capital, Fenbushi, Bitvavocom, Tether and many others has been nothing short of incredible. Your trust, quick action, and solidarity mean everything. We’re moving forward, stronger and more determined than ever. Thank you for standing with us.”

Industry Leaders Take Immediate Action

Several major players in both DeFi and CeFi swiftly mobilized to prevent further movement of stolen funds and uphold market stability:

  • Orbiter, deBridge, SynFutures, MYX, Thruster and Owlto blacklisted exploit-related addresses, preventing unauthorized transfers.
  • Chainalysis rapidly tracked and published the exploiter’s wallet addresses, enabling a coordinated industry-wide response.
  • SIS cross-chain bridge stepped up to block associated addresses, restricting the attacker’s ability to launder assets.
  • Zero Shadows activated its 24/7/365 Global Response team, collaborating closely on Bad Actor Tracing and Identification, Funds Tracing, and Law Enforcement Communications to support the investigation and recovery efforts.
  • Institutional clients, including TMSI, Bayside trading, Mathrix, Wintermute, Cumberland, GSR Markets, maintained their trading positions, reinforcing stability amid uncertainty.

“Their trust in us, despite the circumstances, speaks volumes about the maturity and resilience of this industry,” Ben added. “It shows a defining moment that proves crypto’s strongest players stand together when it matters most.”

A Community That Stands Together

Bybit also acknowledged the unwavering support from its VIP clients, traders, and broader user base. Messages of encouragement and patience from the community have been instrumental as the exchange works around the clock to enhance security measures and safeguard funds.

“While this has been a difficult moment, it is also a powerful reminder of why we are here—to build an open, resilient, and decentralized financial future,” Ben said. “The real work has just started, and with this level of unity in this space, we know we’ll come back even stronger.”

Bybit remains committed to transparency and will continue to provide updates as it implements additional security enhancements. The exchange is working closely with industry leaders to set new standards for crisis management, ensuring the safety and trust of its users while strengthening the broader industry’s defenses against future threats.

#Bybit / #TheCryptoArk

//ENDS

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 60 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press.

For updates, please follow: Bybit’s Communities and Social Media

 

 

DEX Platform DeriW Officially Debuts at the ‘Connecting Legends’ Event in Hong Kong

HONG KONG, Feb. 22, 2025 /PRNewswire/ — DeriW, powered by CoinW, celebrated the official product launch of its cutting-edge gas-free, decentralized perpetual exchange. The CoinW-hosted event took place at the prestigious The Henderson-Cloud 39 rooftop ballroom in Central Hong Kong during the ‘Connecting Legends’ after-party.

This landmark event brought together 400 leading figures from the cryptocurrency sector. It included crypto leaders, innovative projects, key opinion leaders (KOLs), and affiliates.

Interactive Fun and Airdrop Rewards 

The evening began with an engaging short video showcasing DeriW as the pinnacle of trading platforms developed by the seasoned experts at CoinW.

Julia, Head of Marketing at DeriW, captivated the audience by outlining the core advantages of DeriW. She presented its vast opportunities available to traders and affiliates. There was also a sneak peek provided into the eagerly anticipated testnet launch.

Another highlight of the evening was a unique interactive event, designed to engage participants and give them a firsthand experience of DeriW’s user-centric platform.

Attendees had the opportunity to participate in various activities, and winners were rewarded with $USDT airdrops, which will be distributed following the platform’s mainnet launch.

DEX Platform DeriW Officially Debuts at the ‘Connecting Legends’ Event in Hong Kong
DEX Platform DeriW Officially Debuts at the ‘Connecting Legends’ Event in Hong Kong

Designed for the Future 

DeriW sets itself apart by combining the robust security measures of traditional finance with the innovative flexibility of decentralized networks. At its core, DeriW utilizes state-of-the-art Layer 3 technology on Arbitrum Orbit.

This allows it to process up to 80,000 transactions per second without incurring gas fees.

Its technical prowess promises to deliver an unparalleled trading experience that is both cost-effective and exceptionally fast, catering to the needs of both novice and professional traders.

The launch was not only a celebration but also a forward-looking gathering that set the stage for the upcoming testnet phase of DeriW.

This phase is crucial as it allows users to evaluate the platform’s functionalities and provide necessary feedback.

It ensured that DeriW meets community standards and expectations before its full official rollout.

DeriW Ecosystem: A World of Opportunities

Following the Product Launch, DeriW invites Projects and Affiliates to take advantage of opportunities within the DeriW Ecosystem.

Affiliates can benefit from high commission rates of up to 50% and trading rebates for bringing in new traders, while Projects can make use of ample liquidity, token listing opportunities and extensive support for a successful product launch.

Stay Connected

DeriW is committed to transparency and community engagement.

Its official product launch is just the beginning of what promises to be a revolutionary journey in the world of cryptocurrency trading.

For those interested in DeriW’s latest developments and participating in its testnet:

Join DeriW on this exciting journey to transform the digital finance landscape, one transaction at a time.

AB Set to Launch on BingX Exchange, Further Expanding Global Trading Channels

SINGAPORE, Feb. 22, 2025 /PRNewswire/ — AB DAO has officially announced that the AB token will soon be listed on BingX Exchange, with an official announcement to follow upon listing. This move will further expand global trading channels, enhance liquidity, and accelerate the worldwide growth of the AB ecosystem. This milestone will provide users with a seamless and secure trading experience while driving broader adoption of AB in the Web3 space.

As a leading global cryptocurrency exchange, BingX offers a secure and efficient trading environment for users worldwide. The listing of AB on BingX will enable more users to trade, invest, and actively participate in the AB ecosystem.

This listing is an important step in AB DAO’s global expansion strategy, with AB tokens set to be integrated into more major exchanges in the near future, expanding its use cases and accelerating ecosystem growth.

Additionally, investors can also trade $AB on HTX (htx.com), MEXC (mexc.com), and 4E (eeee.com). Furthermore, BitMart (bitmart.com) is also set to list the AB trading pair soon, providing even more trading opportunities for global investors.

Stay Updated on AB DAO

CoinW First to List PI Perpetual Futures with the Highest Leverage – Launches Massive 43,000 USDT Trading Campaign

HONG KONG, Feb. 22, 2025 /PRNewswire/ — CoinW, a leading global cryptocurrency trading platform, proudly announces the listing of Pi Network (PI) perpetual futures, becoming the first major exchange to offer PI perpetual futures with the highest leverage in the market. The listing goes live on February 20, 2025, at 16:00 (UTC+8), coinciding with Pi Network’s highly anticipated mainnet launch. To celebrate this milestone, CoinW is introducing an exciting campaign with cashback rewards, trading competitions, and exclusive bonuses, featuring a total prize pool of 43,000 USDT.

CoinW First to List PI Perpetual Futures with the Highest Leverage – Launches Massive 43,000 USDT Trading Campaign!
CoinW First to List PI Perpetual Futures with the Highest Leverage – Launches Massive 43,000 USDT Trading Campaign!

Pi Network: A Game-Changer with Unprecedented Growth

Since its launch in 2019 by Stanford alumni Nicolas Kokkalis and Chengdiao Fan, Pi Network has grown into a global community of over 18 million KYC-verified users. Its innovative mobile-mining model and user-friendly consensus mechanism—based on the Stellar Consensus Protocol (SCP)—have democratized access to cryptocurrency. With 8 million users already migrated to the closed mainnet, the open mainnet is set to launch on February 20, 2025. Industry analysts expect this milestone to significantly influence PI’s market performance as it becomes accessible to the broader crypto trading ecosystem.

CoinW Leads the Charge with Exclusive Perks

As the first exchange to launch PI perpetual futures, CoinW is setting a new industry standard by offering the highest leverage available. This strategic move aligns with Pi Network’s vast, community-driven growth, providing traders with unique opportunities to capitalize on the anticipated market momentum.

Campaign Duration: February 20, 2025 – March 7, 2025 (UTC+8)

CoinW users can automatically participate in this campaign by trading PI spot or futures and unlocking rewards through four exciting sub-events.

Sub-event 1: New User Exclusive Gifts – Instant Rewards for First Trades

New users who register and trade PI for the first time during the campaign period will enjoy special welcome bonuses:

  • Spot Trading Bonus: First-time PI spot traders with a trading volume of at least 50 USDT will receive 10 USDT in futures bonus.
  • Futures Trading Bonus: First-time PI futures traders with a trading volume of at least 300 USDT will receive 10 USDT in futures bonus.
  • Extra Super Bonus: New users who registered after February 13, 2025, and trade PI futures will receive an additional 10-200 USDT in futures bonus.
    • Total prize pool: 10,000 USDT – first come, first served!

Sub-event 2: Trading Leaderboard – Compete for Top Rewards!

During the campaign, users who trade PI will be ranked based on their total trading volume, with the top traders earning significant USDT rewards:

Spot Trading Leaderboard Rewards:

  • 1st place: 1,000 USDT in PI (Minimum 100,000 USDT trading volume)
  • 2nd place: 600 USDT in PI (Minimum 80,000 USDT trading volume)
  • 3rd place: 400 USDT in PI (Minimum 50,000 USDT trading volume)
  • Ranks 4-100: Share 6,000 USDT in PI proportionally based on trading volume

Futures Trading Leaderboard Rewards:

  • 1st place: 1,000 USDT in PI (Minimum 6,000,000 USDT trading volume)
  • 2nd place: 600 USDT in PI (Minimum 3,000,000 USDT trading volume)
  • 3rd place: 400 USDT in PI (Minimum 2,000,000 USDT trading volume)
  • Ranks 4-100: Share 8,000 USDT in PI proportionally based on trading volume

Sub-event 3: Cashback Airdrop – Get Rewarded for Buying High!

To boost trading momentum, CoinW is introducing an exclusive cashback airdrop! The top 10 highest buy orders during the campaign will receive a 10% cashback airdrop, with 5,000 USDT maximum.

Sub-event 4: Invite Friends and Earn Together!

CoinW believes in rewarding its community. Simply invite new users to trade PI, and both you and your referrals will earn rewards:

  • Invite a new user who completes at least 100 USDT in spot trading or 300 USDT in futures trading, and both users will receive 3 USDT in PI rewards.
  • Total prize pool: 10,000 USDT in PI!

About CoinW

CoinW is a globally recognized cryptocurrency exchange known for its secure, user-friendly platform and innovative trading products. Operating in over 200 countries and regions, CoinW remains committed to empowering the crypto community with advanced tools and accessible trading experiences.

Website: https://www.coinw.com/

Twitter Official:https://twitter.com/CoinWOfficial

Telegram: https://t.me/coinwoff

YouTube Official: https://www.youtube.com/@CoinWOfficial

Linkedin: https://www.linkedin.com/company/coinwofficial/